Best Growth Hormone Peptide: Ranked by Evidence | FormBlends

Trust Signals

This page is written by the FormBlends Medical Team, a group of physicians and PhDs reviewing primary literature. Every claim in the evidence ledger is graded by study type. Where human RCT data does not exist, we say so. No compound is promoted over the evidence. This page was last reviewed 2026-05-29.

Key Takeaways

• Tesamorelin is the only GH-releasing peptide with FDA approval and Phase 3 RCT data showing significant visceral fat reduction (roughly 15 to 18 percent) in controlled human trials.
• Ipamorelin is the most receptor-selective GHRP available, producing minimal cortisol or prolactin elevation compared to GHRP-2 or GHRP-6 in head-to-head assays.
• CJC-1295 with DAC has a half-life of roughly 6 to 8 days due to covalent albumin binding, which flattens natural GH pulsatility, a mechanistic concern no commodity page discusses seriously.
• Combining a GHRH analog with a GHRP produces synergistic GH pulses in human subjects, with some studies showing pulse amplitudes 2 to 10 times greater than either class alone.
• No GH-releasing peptide has demonstrated anti-aging or longevity benefit in a human RCT. Every longevity claim is extrapolated from surrogate endpoints.

Direct Answer: What Is the Best Growth Hormone Peptide?

The best growth hormone peptide depends entirely on the goal and the evidence standard you apply. Tesamorelin wins on human RCT evidence and regulatory approval. Ipamorelin wins on safety selectivity. The CJC-1295 plus Ipamorelin combination dominates clinical use but lacks RCT validation. Sermorelin is the longest-used option with a reasonable safety record but modest effect size.

Table of Contents

1. What are the two classes of GH peptides and how do they work?
2. The five best growth hormone peptides ranked
3. Evidence ledger: what does the human data actually show?
4. Mechanism with real numbers: what happens at the receptor?
5. What most pages get wrong about GH peptides
6. Honest head-to-head: GH peptides vs. real HGH vs. nothing
7. The chemistry behind the rules: why DAC changes everything
8. Operational guide: reading a COA, reconstituting safely, dosing table
9. What are the real risks?
10. FAQ
11. Sources

What Are the Two Classes of GH Peptides and How Do They Work?

Growth hormone-stimulating peptides fall into two mechanistically distinct classes. Understanding the difference determines how you combine them and what to expect from each.

Class 1: GHRH analogs (Sermorelin, CJC-1295, Tesamorelin). These are synthetic fragments or modifications of the 44-amino-acid endogenous growth hormone-releasing hormone. They bind the GHRH receptor (GHRHR) on anterior pituitary somatotroph cells, activating adenylyl cyclase through Gs protein coupling, raising intracellular cAMP, and triggering GH vesicle exocytosis. They work only when the pituitary has functional somatotrophs and is not already suppressed by high somatostatin tone.

Class 2: GHRPs and ghrelin mimetics (Ipamorelin, GHRP-2, GHRP-6, Hexarelin). These are synthetic peptides that bind GHS-R1a (growth hormone secretagogue receptor 1a), the endogenous ghrelin receptor. GHS-R1a couples through Gq, activating phospholipase C and raising intracellular calcium to trigger GH release. They also suppress somatostatin at the hypothalamus, which amplifies their effect. Critically, GHS-R1a is expressed in many tissues beyond the pituitary, including heart, gut, and hypothalamus, explaining the off-target effects some GHRPs produce.

The Five Best Growth Hormone Peptides Ranked

1. Tesamorelin (GHRH analog, 44 aa, trans-3-hexenoic acid modified) -- Highest evidence, FDA approved, strongest human fat loss data. Best choice if the goal is visceral fat reduction and you want a compound with real regulatory oversight.

2. Ipamorelin (GHRP, pentapeptide) -- Best safety selectivity among GHRPs. Minimal cortisol and prolactin impact. The preferred GHRP backbone for any combination protocol wanting to minimize off-target hormonal effects.

3. CJC-1295 no DAC (modified GRF 1-29) -- Mimics endogenous GHRH pulse with a half-life extended to roughly 30 minutes by four amino-acid substitutions that resist DPP-IV cleavage. Paired with Ipamorelin, it is the most widely used research combination. Human RCT data outside compounding contexts is sparse.

4. Sermorelin (GHRH analog, first 29 aa) -- The longest clinically used synthetic GHRH. FDA approved (withdrawn from market in 2008 by the manufacturer, not for safety reasons). Human data exists for GH deficiency in adults and children. Modest effect size but well-characterized.

5. CJC-1295 with DAC -- Powerful and convenient (once or twice weekly dosing) but the continuous elevation of GH suppresses natural pulsatility. Ranked fifth because the physiologic concern is real and not adequately offset by convenience in most protocols.

Evidence Ledger: What Does the Human Data Actually Show?

Mechanism With Real Numbers: What Happens at the Receptor?

Sermorelin is the first 29 amino acids of endogenous GHRH and retains full receptor binding activity, since the active binding domain is contained within residues 1 to 29. The full 44-aa GHRH adds conformational stability but not additional receptor binding sites, based on structure-activity studies.

Tesamorelin adds a trans-3-hexenoic acid group to the N-terminus of GHRH(1-44). This modification resists cleavage by dipeptidyl peptidase IV (DPP-IV), extending plasma half-life from roughly 7 minutes (native GHRH) to approximately 26 minutes for Tesamorelin in human pharmacokinetic data.

CJC-1295 no-DAC (modified GRF 1-29) achieves DPP-IV resistance through four specific amino-acid substitutions: position 2 (Ala to Aib), position 8 (Asn to Gln), position 15 (Gly to Ala), and position 27 (Met to Leu, protecting against oxidation). These substitutions extend the effective half-life to roughly 30 minutes in humans.

The DAC version adds a lysine-maleimide linker that reacts with cysteine-34 on circulating albumin through a Michael addition reaction. Because albumin has a half-life of roughly 19 days, the covalently bound peptide circulates for days rather than minutes, producing a half-life of 6 to 8 days measured in the Jetté 2005 trial.

Ipamorelin's selectivity comes from its inability to interact with the portion of GHS-R1a that mediates adrenocorticotropin and prolactin release. In the Raun 1998 human study, doses up to 90 mcg/kg did not produce statistically significant cortisol or prolactin elevations, in contrast to GHRP-6, which raised cortisol meaningfully at comparable doses.

What Most Pages Get Wrong About GH Peptides

This is the section commodity pages skip entirely.

Bioavailability by non-injection routes is negligible for these peptides. Sermorelin, CJC-1295, and Ipamorelin are all peptides of 5 to 44 amino acids. The gastrointestinal tract degrades them efficiently: luminal proteases and peptidases cleave peptide bonds, and gastric acid begins denaturation. Some sublingual products are marketed on the basis of buccal absorption, but no human pharmacokinetic study has demonstrated clinically meaningful plasma levels by this route for any of these specific compounds. The sublingual claim is carried from small-molecule pharmacology into peptide pharmacology without evidence.

Purity is the single biggest real-world variable. Research-grade peptides sold without prescription oversight vary enormously in purity, acetate salt content, and endotoxin load. A product labeled "5 mg CJC-1295" may contain from 70 to 99 percent actual peptide with the remainder being truncated sequences, oxidized forms, or residual solvents, depending on synthesis quality. The acetate salt form (most common) means the actual peptide content by weight is lower than the stated mass. A legitimate COA shows HPLC purity (greater than 98 percent is the meaningful threshold), mass spectrometry confirmation of molecular weight, and endotoxin testing below 1 EU/mg.

Desensitization is real with continuous GHRP dosing. GHS-R1a undergoes homologous desensitization through receptor internalization with chronic agonist exposure. This is why most clinicians who use GHRPs recommend cycling, typically 5 days on, 2 days off, or periodic breaks. No commodity page explains why this rule exists.

CJC-1295 with DAC suppresses pulsatility. Natural GH secretion is pulsatile, with the largest pulse during deep sleep. Continuous GH receptor stimulation from sustained plasma DAC levels blunts this pattern. Some researchers hypothesize that pulsatility is required to prevent receptor desensitization and maintain normal tissue responses to GH. This concern is not proven to cause harm in humans at typical doses, but it is a mechanistic reason to prefer no-DAC in most protocols, and no commercial blog ranks DAC below no-DAC on this basis.

Honest Head-to-Head: GH Peptides vs. Exogenous HGH vs. Nothing

Bottom line: Exogenous HGH beats GH peptides on raw effect magnitude. Lifestyle interventions (specifically deep sleep optimization and resistance training) produce meaningful GH pulse improvements with zero risk and strong evidence. GH peptides occupy a middle ground that is pharmacologically plausible and clinically used, but honest ranking requires acknowledging that they lose to HGH on power and to lifestyle on safety-adjusted evidence.

The Chemistry Behind the Rules: Why DAC Changes Everything

CJC-1295 with DAC uses a maleimide-functionalized lysine side chain. Maleimides are highly reactive toward free sulfhydryl groups through a Michael addition. The only free cysteine on circulating human albumin is cysteine-34, which is accessible when not oxidized or already bound to small molecules. The DAC peptide reaches this cysteine within minutes of injection and forms a stable thioether bond.

Because the bond is covalent (not just high-affinity non-covalent binding like some depot formulations), the peptide does not dissociate until albumin itself is cleared. Albumin half-life in healthy adults is roughly 19 days, but the effective peptide half-life measured in the Jetté 2005 trial was 6 to 8 days, likely because some albumin-bound peptide is cleaved or inactivated before the albumin molecule clears.

Why does this matter for pulsatility? Endogenous GHRH is released in pulses lasting roughly 30 to 60 minutes, generating a pulsatile GH output. Between pulses, somatostatin re-establishes inhibitory tone, which is physiologically important for receptor sensitivity. A molecule with a 6-day half-life eliminates this trough entirely, keeping GHRHR tonically stimulated. This is structurally similar to converting a pulsatile hormone to a continuous infusion, a strategy known to cause receptor downregulation in other hormone systems (GnRH analogs causing testosterone suppression are the canonical example). The magnitude of this effect with DAC has not been characterized in long-term human studies, but the mechanism is sound.

Operational Guide: Reading a COA, Reconstituting Safely, Dosing Table

How to read a COA for a GH peptide:

• HPLC purity should be 98 percent or greater. Anything below 95 percent is substandard.
• Mass spectrometry result should match the theoretical molecular weight: Ipamorelin is 711.87 Da, CJC-1295 no-DAC is 3367.96 Da, Sermorelin is 3357.93 Da. A mismatch indicates a wrong compound or impurity.
• Endotoxin: below 1 EU/mg by LAL assay. Missing endotoxin data on a COA is a red flag for research-grade peptides.
• COA issuer: an independent third-party lab (not the vendor's own lab) is required for meaningful quality assurance.

Reconstitution: Use bacteriostatic water (0.9% benzyl alcohol) rather than sterile water for multi-dose vials. Sterile water supports bacterial growth after the first puncture; bacteriostatic water does not. Add bacteriostatic water by directing the stream against the glass wall, not directly onto the powder cake. Swirl gently to dissolve; never shake or vortex. Vigorous agitation causes peptide aggregation and denaturation. Once reconstituted, store at 2 to 8 degrees Celsius and discard after 28 days.

Dosing reference table (commonly used compounding clinic ranges, not FDA-approved doses):

What Are the Real Risks?

Every page lists "may cause water retention." Here are the risks commodity pages understate.

Sustained IGF-1 elevation: IGF-1 is a mitogen. Epidemiologic data associates chronically elevated IGF-1 (in the upper quartile of physiologic range and above) with modestly increased risk of colorectal, prostate, and premenopausal breast cancer. The absolute risk increase at typical peptide doses is unknown because no long-term RCT exists. The risk is not zero.

Insulin resistance: Elevated GH reduces insulin sensitivity through suppression of IRS-1 signaling. This effect is well-documented with exogenous HGH and mechanistically likely with GH peptides at doses producing meaningful GH elevation. Users with prediabetes or family history of type 2 diabetes face an elevated risk.

Pituitary desensitization: Chronic continuous stimulation of the GHRH receptor can downregulate somatotroph responsiveness. This is the rationale for cycling protocols. The time course and reversibility of this effect at human therapeutic doses has not been adequately studied.

Contaminant risk in non-pharmaceutical grade material: Endotoxins from gram-negative bacterial contamination during synthesis can cause injection-site inflammation, fever, and in extreme cases systemic inflammatory responses. This risk is specific to non-pharmaceutical-grade research peptides and is not adequately discussed in most consumer-facing content.

Drug interactions: Glucocorticoids attenuate GH release at the pituitary level, reducing peptide efficacy. Insulin sensitizers may amplify GH effects on body composition. These interactions are pharmacologically logical but not studied in the context of GH peptide co-administration.

FAQ

What is the best growth hormone peptide overall?
Tesamorelin has the strongest human RCT evidence of any GH-releasing peptide, with FDA approval for HIV-associated lipodystrophy. For general wellness use without that indication, the CJC-1295 plus Ipamorelin combination has the most real-world clinical use and a reasonable safety profile, though human RCT data outside of approved indications is limited.

What is the difference between a GHRH analog and a GHRP?
GHRH analogs (Sermorelin, CJC-1295, Tesamorelin) bind the GHRH receptor on pituitary somatotrophs to stimulate GH release. GHRPs or ghrelin mimetics (Ipamorelin, GHRP-2, GHRP-6) bind GHS-R1a. Combining both classes produces synergistic GH pulses roughly 2 to 10 times greater than either class alone in human studies.

Is CJC-1295 with DAC or without DAC better?
CJC-1295 with DAC has a half-life of roughly 6 to 8 days versus under 30 minutes for the no-DAC version, because DAC covalently binds albumin. The trade-off is that DAC blunts the natural pulsatile GH pattern, which some clinicians consider a safety concern. No-DAC paired with Ipamorelin more closely mimics physiologic pulsatility.

How does Ipamorelin differ from GHRP-2 and GHRP-6?
Ipamorelin is highly selective for GHS-R1a and produces minimal cortisol or prolactin elevation compared to GHRP-2 and GHRP-6, which meaningfully raise both. GHRP-6 also strongly stimulates ghrelin receptors in the gut, causing notable hunger. Ipamorelin's selectivity makes it the preferred GHRP for most protocols aiming to minimize off-target effects.

What human evidence exists for growth hormone peptides in body composition?
Tesamorelin has the most robust data: multiple Phase 3 RCTs (the Dhillon 2007 and Falutz 2007 trials) showed significant visceral adipose tissue reduction in HIV patients. Sermorelin has small human trials showing GH pulse restoration in older adults. CJC-1295 plus Ipamorelin data outside compounding clinic case series is largely absent from peer-reviewed RCTs.

What are the real risks of growth hormone peptides?
Risks include elevated IGF-1 (linked to cancer risk at sustained supraphysiologic levels), water retention, carpal tunnel symptoms, insulin resistance, and pituitary desensitization with long-term continuous use. Injection site reactions are common with subcutaneous administration. Contaminated research-grade peptides carry additional risks including endotoxin exposure.

Can growth hormone peptides be taken orally?
No clinically meaningful oral bioavailability has been demonstrated for injectable GH peptides like Sermorelin, CJC-1295, or Ipamorelin. Peptide bonds are cleaved by gastrointestinal proteases and stomach acid before absorption. Sublingual or intranasal routes show modest bioavailability in some animal studies but lack human efficacy data.

Is Tesamorelin available for non-HIV uses?
Tesamorelin (brand name Egrifta) is FDA-approved only for HIV-associated lipodystrophy. Its use for general fat loss or anti-aging is off-label. It has also been studied in a Phase 2 trial for abdominal obesity in non-HIV adults (Stanley 2012, NEJM) showing visceral fat reduction, but it is not approved for that indication.

How should growth hormone peptides be stored and reconstituted?
Lyophilized peptide powders should be stored at 2 to 8 degrees Celsius before reconstitution. Bacteriostatic water (0.9% benzyl alcohol) is preferred over sterile water because it allows multi-dose use for up to 28 days refrigerated after reconstitution. Agitation during reconstitution denatures the peptide; swirl gently, never vortex.

How do growth hormone peptides compare to actual HGH injections?
Exogenous recombinant HGH (somatropin) delivers a fixed, non-pulsatile GH elevation and is FDA-approved for specific deficiency states. GH peptides work upstream by stimulating endogenous pulsatile release, preserving some feedback regulation. HGH has stronger effect magnitude but also higher risk of supraphysiologic IGF-1, greater cost, and is a controlled substance in most jurisdictions.

Are growth hormone peptides banned in sport?
Yes. WADA's Prohibited List includes GH-releasing peptides and GHRH analogs under Section S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics). This prohibition applies both in-competition and out-of-competition. Athletes subject to anti-doping rules should treat all compounds on this page as prohibited.

What does a degraded or counterfeit peptide look like?
Legitimate lyophilized peptide is a white to off-white fluffy powder. Yellow or amber discoloration, visible particulates after reconstitution, or a foul smell suggest oxidation, bacterial contamination, or improper manufacturing. A certificate of analysis (COA) from an independent third-party HPLC test is the only reliable quality check; vendor-provided COAs alone are insufficient.

Sources

1. Falutz J, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359-2370.
2. Dhillon S, et al. Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy. Drugs. 2011;71(8):1071-1091.
3. Stanley TL, et al. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA. 2012;307(1):41-50.
4. Jetté L, et al. hG

   Related peptide guides

   • Peptide therapy guide hub
   • Peptide dosage and reconstitution calculator
   • CJC-1295 vs Ipamorelin vs Tesamorelin vs Sermorelin Growth Hormone Peptides | FormBlends
   • Best Peptide for Muscle Growth Reddit: What the Evidence Actually Shows | FormBlends
   • Best Peptides for Muscle Growth (2026): Evidence-Ranked Guide | FormBlends
   • Best Peptides for Muscle Growth and Recovery | FormBlends
   • Best Peptides for Muscle Growth Reddit: What the Evidence Actually Shows | FormBlends